Rheumatoid Factor & Anti-CCP
Rheumatoid Factor (RF) & Anti-Cyclic Citrullinated Peptide Antibody (Anti-CCP)
What it is
Rheumatoid factor (RF) is an autoantibody — most commonly IgM class — directed against the Fc (constant) region of IgG immunoglobulins. Its name reflects its historical discovery in patients with rheumatoid arthritis, though RF is not specific to RA: it is elevated in other autoimmune diseases (Sjögren's syndrome, SLE, mixed connective tissue disease), chronic infections (hepatitis B and C, endocarditis, tuberculosis), and in approximately 5–10% of healthy adults over 50. Anti-CCP (anti-cyclic citrullinated peptide antibody) targets citrullinated proteins — proteins in which arginine residues have been converted to citrulline by the enzyme peptidylarginine deiminase (PAD), a post-translational modification that occurs in the synovium during chronic inflammation. Anti-CCP antibodies are detected by enzyme immunoassay using synthetic cyclic citrullinated peptide antigens. Anti-CCP is substantially more specific for rheumatoid arthritis than RF — approximately 95–98% specificity versus 75–85% for RF — meaning a positive anti-CCP is a much stronger signal for RA than a positive RF alone. The combination of RF and anti-CCP is more diagnostically sensitive than either alone.
Why we measure it
Rheumatoid arthritis is the most common inflammatory arthritis, affecting approximately 0.5–1% of the global population. Left untreated, RA causes progressive joint destruction, deformity, and disability — along with systemic manifestations including accelerated cardiovascular disease, interstitial lung disease, and increased infection risk. The pivotal discovery, supported by multiple prospective studies including analyses of biobanked military and blood donor samples, is that RF and anti-CCP autoantibodies are detectable years to decades before the clinical onset of joint symptoms — entering a preclinical phase during which the adaptive immune response against citrullinated self-proteins develops gradually. In one study, anti-CCP was detectable a mean of 4.5 years before RA diagnosis. This window is clinically critical: disease-modifying antirheumatic drugs (DMARDs) — particularly methotrexate and biological agents targeting TNF, IL-6, and B-cells — are most effective when started before significant joint destruction has occurred. Early intervention changes the disease trajectory. Annual anti-CCP and RF testing allows detection of seroconversion — the transition from autoantibody-negative to positive — in the preclinical phase, enabling monitoring, risk factor modification, and timely specialist review before joint symptoms begin.
Why every 12 months
Annual testing is appropriate for autoimmune surveillance. Autoantibody development in inflammatory arthritis occurs slowly; annual measurement provides sufficient temporal resolution to detect seroconversion and to monitor titre changes in established seropositive individuals. A new positive anti-CCP in a previously negative individual — even in the absence of joint symptoms — warrants rheumatology review.
What movement means
RF and anti-CCP are each reported as a quantitative value (Units/mL for RF; Units/mL or as a ratio for anti-CCP) with a laboratory-defined positivity threshold. Both tests have some continuous association between titre and disease activity/prognosis — higher anti-CCP titres are associated with a more erosive RA course. Neither test is diagnostic in isolation; clinical symptoms, examination, and imaging are required for RA diagnosis.
Negative
RF < 14 IU/mL · Anti-CCP < 17 U/mL (laboratory-specific thresholds vary)
Negative for both markers. Seronegative RA accounts for approximately 30–40% of RA cases — a negative result does not exclude RA if symptoms are present. Annual retesting in asymptomatic individuals.
Aletaha D et al., 2010 ACR/EULAR Classification Criteria for RA, Arthritis & Rheumatism, 2010 — doi:10.1002/art.27584
Low Positive
RF 14 – 50 IU/mL · Anti-CCP 17 – 50 U/mL (laboratory-specific)
Low positive titre. For RF, low positivity in older adults may be a non-pathological finding. For anti-CCP, even low positivity is more specific for RA given the high specificity of the test. In the presence of any joint symptoms, rheumatology review is appropriate.
Aletaha D et al., 2010 ACR/EULAR Classification Criteria for RA, Arthritis & Rheumatism, 2010 — doi:10.1002/art.27584
High Positive
RF > 50 IU/mL · Anti-CCP > 50 U/mL (laboratory-specific)
High titre. For anti-CCP, high positivity substantially increases the probability of RA and is associated with a more erosive disease course. For RF, high titres are also associated with extra-articular RA manifestations. Rheumatology review is recommended regardless of current symptoms.
van der Helm-van Mil AH et al., Arthritis & Rheumatism, 2005 — doi:10.1002/art.21519
In the protocol
References
- 1.
Aletaha D, Neogi T, Silman AJ, et al.. “2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative.” Arthritis & Rheumatism. 2010.
- 2.
Nielen MM, van Schaardenburg D, Reesink HW, et al.. “Specific Autoantibodies Precede the Symptoms of Rheumatoid Arthritis: A Study of Serial Measurements in Blood Donors.” Arthritis & Rheumatism. 2004.
- 3.
van der Helm-van Mil AHM, Verpoort KN, Breedveld FC, Toes REM, Huizinga TWJ. “Antibodies to Citrullinated Proteins and Differences in Clinical Progression of Rheumatoid Arthritis.” Arthritis Research & Therapy. 2005.
- 4.
Smolen JS, Aletaha D, McInnes IB. “Rheumatoid Arthritis.” The Lancet. 2016.